Salix Pharmaceuticals Partners with Bellamy Young
Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting...
Brain
Synchrony Symposium 2023 Advances Research and Clinical Care for Neurodevelopmental Disorders, Including Autism
Dr. Mario Capecchi, Nobel Laureate at University of Utah, to Deliver Keynote on Research to Understand Symptoms Prevalent in Individuals...
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated CareVancouver, British Columbia--(Newsfile...
Relievant Medsystems Announces Positive Coverage Policy for the Intracept Procedure from Anthem Blue Cross and Blue Shield
Expands access to vertebrogenic pain treatment for 36 million patientsMINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company...
DiagnaMed Launches New Healthcare Provider Network Program for CERVAI™ Brain Health AI Platform in Canada and the USA
Program provides healthcare providers access to Diagnamed’s novel brain health AI platform Figure 1. Demonstration of CERVAI™ Brain Age™ SessionTORONTO,...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent...
Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)
NME is a progressive, typically fatal autoimmune disease characterized by brain inflammation, that has no disease-modifying treatment options availableSAN DIEGO...
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on...
AlzeCure Presents at Redeye Neurology Theme Event on October 11
STOCKHOLM, SWEDEN / ACCESSWIRE / October 3, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
CCA Industries, Inc. Announces the Sale of Bikini Zone Brand
FORT WASHINGTON, PA / ACCESSWIRE / October 2, 2023 / CCA Industries, Inc. (OTC Pink:CAWW) has sold its Bikini Zone...
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected...
Interim results for the six months ended 30 June 2023
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa...
Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB
EDINBURGH and CAMBRIDGE, United Kingdom, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, continues...
Vaccinex Announces Pricing of $9.6 Million Public Offering
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Medicenna Announces Results of Annual and Special Meeting of Shareholders
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage...
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation...
Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials
Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit from this joint effort to...
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their...
Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece
-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be...
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a...